After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
BridgeBio Pharma Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of BridgeBio Pharma Inc is $5.26B. A total of 0.84 million shares were traded on the day, compared to an average of 1.70M shares.
In the most recent transaction, Scott Randal W. sold 2,500 shares of BBIO for 34.00 per share on Mar 01 ’24. After the transaction, the Director now owns 6,500 company shares. In a previous transaction on Feb 15 ’24, Valantine Hannah sold 2,915 shares at 37.75 per share. BBIO shares that Director owns now total 1,764.
Among the insiders who sold shares, Valantine Hannah disposed of 2,915 shares on Jan 16 ’24 at a per-share price of $37.97. This resulted in the Director holding 1,764 shares of BBIO after the transaction. In another insider transaction, MCCORMICK FRANK sold 100,000 shares at $42.06 per share on Dec 26 ’23. Company shares held by the Director now total 627,689.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, BBIO has a high of $44.32 and a low of $12.75.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. BBIO’s latest balance sheet shows that the firm has $836.66M in Cash & Short Term Investments as of fiscal 2021. There were $1.73B in debt and $135.07M in liabilities at the time. Its Book Value Per Share was -$5.61, while its Total Shareholder’s Equity was -$865.58M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BBIO is Buy with a score of 4.75.
